GSA Capital Partners LLP Has $777,000 Stock Position in Anika Therapeutics, Inc. (NASDAQ:ANIK)

GSA Capital Partners LLP cut its stake in Anika Therapeutics, Inc. (NASDAQ:ANIK) by 20.4% in the third quarter, HoldingsChannel reports. The institutional investor owned 31,475 shares of the biotechnology company’s stock after selling 8,087 shares during the quarter. GSA Capital Partners LLP’s holdings in Anika Therapeutics were worth $777,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Stonepine Capital Management LLC boosted its stake in shares of Anika Therapeutics by 171.4% in the 2nd quarter. Stonepine Capital Management LLC now owns 165,397 shares of the biotechnology company’s stock valued at $4,190,000 after purchasing an additional 104,448 shares in the last quarter. Acadian Asset Management LLC boosted its position in Anika Therapeutics by 25.8% in the first quarter. Acadian Asset Management LLC now owns 421,427 shares of the biotechnology company’s stock valued at $10,701,000 after buying an additional 86,436 shares in the last quarter. Riverwater Partners LLC grew its stake in Anika Therapeutics by 539.1% during the third quarter. Riverwater Partners LLC now owns 101,996 shares of the biotechnology company’s stock worth $2,552,000 after buying an additional 86,037 shares during the last quarter. Meros Investment Management LP increased its holdings in shares of Anika Therapeutics by 25.0% during the second quarter. Meros Investment Management LP now owns 212,714 shares of the biotechnology company’s stock worth $5,388,000 after buying an additional 42,587 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Anika Therapeutics by 6.9% in the second quarter. Renaissance Technologies LLC now owns 598,229 shares of the biotechnology company’s stock valued at $15,153,000 after acquiring an additional 38,412 shares during the last quarter. Institutional investors own 91.53% of the company’s stock.

Anika Therapeutics Stock Up 1.5 %

Shares of ANIK stock opened at $17.25 on Monday. The stock has a 50-day moving average of $22.96 and a 200-day moving average of $25.03. Anika Therapeutics, Inc. has a one year low of $16.00 and a one year high of $29.11.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Barrington Research dropped their price target on Anika Therapeutics from $37.00 to $25.00 and set an “outperform” rating for the company in a report on Friday, November 1st. StockNews.com downgraded shares of Anika Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, November 4th.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.